Talphera Inc. (TLPH) - Total Assets
Based on the latest financial reports, Talphera Inc. (TLPH) holds total assets worth $30.74 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Talphera Inc. for net asset value and shareholders' equity analysis.
Talphera Inc. - Total Assets Trend (2008–2024)
This chart illustrates how Talphera Inc.'s total assets have evolved over time, based on quarterly financial data.
Talphera Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Talphera Inc.'s total assets of $30.74 Million consist of 51.6% current assets and 48.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 48.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $8.82 Million | 48.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Talphera Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Talphera Inc. worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Talphera Inc.'s current assets represent 51.6% of total assets in 2024, a decrease from 92.5% in 2008.
- Cash Position: Cash and equivalents constituted 48.6% of total assets in 2024, up from 26.8% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 48.4% of total assets.
Talphera Inc. Competitors by Total Assets
Key competitors of Talphera Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Talphera Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.83 | 4.42 | 2.66 |
| Quick Ratio | 6.83 | 4.42 | 2.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $18.71 Million | $9.43 Million | $29.20 Million |
Talphera Inc. - Advanced Valuation Insights
This section examines the relationship between Talphera Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.11 |
| Latest Market Cap to Assets Ratio | 2.28 |
| Asset Growth Rate (YoY) | -10.6% |
| Total Assets | $18.24 Million |
| Market Capitalization | $41.54 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Talphera Inc.'s assets at a significant premium (2.28x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Talphera Inc.'s assets decreased by 10.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Talphera Inc. (2008–2024)
The table below shows the annual total assets of Talphera Inc. from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $18.24 Million | -10.59% |
| 2023-12-31 | $20.39 Million | -57.05% |
| 2022-12-31 | $47.49 Million | -39.04% |
| 2021-12-31 | $77.89 Million | +17.49% |
| 2020-12-31 | $66.30 Million | -27.43% |
| 2019-12-31 | $91.36 Million | -24.21% |
| 2018-12-31 | $120.53 Million | +59.54% |
| 2017-12-31 | $75.55 Million | -24.44% |
| 2016-12-31 | $99.99 Million | -21.75% |
| 2015-12-31 | $127.78 Million | +47.87% |
| 2014-12-31 | $86.42 Million | -21.46% |
| 2013-12-31 | $110.03 Million | +70.54% |
| 2012-12-31 | $64.52 Million | +58.00% |
| 2011-12-31 | $40.84 Million | +497.88% |
| 2010-12-31 | $6.83 Million | -52.87% |
| 2009-12-31 | $14.49 Million | -36.10% |
| 2008-12-31 | $22.68 Million | -- |
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulat… Read more